Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2023
Reporting Period: Event date October 20, 2023
This filing reports a corporate governance amendment approved by the Board of Directors regarding the Company's Amended and Restated Bylaws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a bylaw amendment and does not contain financial performance data.
Material Changes
The Board of Directors approved an amendment to the Company's Bylaws effective immediately on October 20, 2023. The material change is as follows:
- Quorum Requirement Reduction: The quorum requirement for stockholder meetings was reduced from a majority (more than 50%) of voting power to at least one-third (33.3%) of voting power of common stock issued and outstanding and entitled to vote.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the description of the bylaw amendment and the incorporation of the full text of the amendment as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the full text of Amendment No. 1 to the Amended and Restated Bylaws filed as Exhibit 3.1.
- Confirm the impact of the reduced quorum requirement (one-third) on future stockholder meeting validity and potential governance outcomes.
- Note that this filing contains no financial updates or operational results.